The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma

Melanoma is one of the deadliest skin cancers having a five-year survival rate around 15–20%. An overactivated MAPK/AKT pathway is well-established in BRAF mutant melanoma. Vemurafenib (Vem) was the first FDA-approved BRAF inhibitor and gained great clinical success in treating late-stage melanoma....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Pharmacol
Hlavní autoři: Cui, Hongmei, Wang, Qinghui, Miller, Duane D., Li, Wei
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2021
Témata:
Pharmacology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8027488/
https://ncbi.nlm.nih.gov/pubmed/33841154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.637098
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky